PBC patients receiving linerixibat saw statistically significant improvement in cholestatic pruritus - or relentless itch.

PBC is a rare and chronic liver disease that disproportionately affects women. The condition causes the small bile ducts in ...

Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...

Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the ...

Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

Individuals with primary biliary cholangitis and diabetes may experience worse outcomes, such as progression to end-stage liver disease.

GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its ...

Sunshine Biopharma introduces new drug, Ursodiol for management of cholestatic liver diseases, including PBC: Fort Lauderdale, Florida Monday, November 25, 2024, 15:00 Hrs [IST] S ...

Journalist Annie Lowrey has a rare disease that causes a near-constant itch that doesn't respond to most treatments. She ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint ... The study enrolled 238 people with ...

In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval ...